Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellcura ASA Enters Asia with First Sale to IVF Institution in China


Thursday, 17 Jan 2013 06:50am EST 

Cellcura ASA announced that it steps into Asia with the first sale of its ART Lab solution to Peking University Third Hospital IVF Center, People's Republic of China. The CellCura ART Lab Solution will be immediately operational for routine treatment in the clinic, which is looking to expand its treatment capacity in the next few years, cutting down on ever increasing waiting lists in the region. This first Chinese contract has been developed in partnership with a distributor Guangzhou Haoxin Instrument Co Ltd and their subsidiary Hong Kong Long Sense Development Ltd. The financial details were not disclosed. 

Company Quote

2.41
0.02 +0.84%
7 Jul 2014